Park West Asset Management LLC Sells 70,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Park West Asset Management LLC reduced its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 3.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,792,988 shares of the biopharmaceutical company's stock after selling 70,000 shares during the quarter. Park West Asset Management LLC owned 3.65% of Theravance Biopharma worth $16,872,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in Theravance Biopharma by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock worth $8,121,000 after acquiring an additional 4,823 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after purchasing an additional 95,304 shares during the period. Northern Trust Corp lifted its stake in shares of Theravance Biopharma by 1.6% during the 4th quarter. Northern Trust Corp now owns 389,980 shares of the biopharmaceutical company's stock valued at $3,670,000 after buying an additional 6,198 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Theravance Biopharma by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after buying an additional 2,060 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Theravance Biopharma by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company's stock valued at $2,151,000 after buying an additional 7,620 shares in the last quarter. Institutional investors own 99.10% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $11.33.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, April 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 370,038 shares in the company, valued at $3,330,342. This trade represents a 1.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 6.90% of the company's stock.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock traded down $0.02 during midday trading on Friday, reaching $10.37. 236,008 shares of the company's stock traded hands, compared to its average volume of 272,236. The stock has a 50 day moving average of $9.16 and a 200-day moving average of $9.25. The company has a market cap of $518.51 million, a PE ratio of -10.27 and a beta of -0.10. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). The company had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. On average, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.